MedTrace Logo

PhysioFlow to Detect Cardiotoxicity in Chemo

NCT02220569 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2015-09-23

No results posted yet for this study

Summary

PULSE-ECCho will focus on trying to detect cardiotoxicity in cancer patients receiving chemotherapy early on in order to avoid irreversible damage. In addition to that, we will test if the PhysioFlow is non-inferior to the conventional MUGA scan.

Conditions

  • Chemotherapy, Cancer, Cardiotoxicity, Physioflow

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Nathaniel Bouganim, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02220569 on ClinicalTrials.gov